Cargando…
A Randomized Trial of Lipid Metabolism Modulation with Fenofibrate for Acute Coronavirus Disease 2019
BACKGROUND: Abnormal cellular lipid metabolism appears to underlie SARS-CoV-2 cytotoxicity and may involve inhibition of peroxisome proliferator activated receptor alpha (PPARα). Fenofibrate, a PPAR-α activator, modulates cellular lipid metabolism. Fenofibric acid has also been shown to affect the d...
Ejemplares similares
-
A randomized clinical trial of lipid metabolism modulation with fenofibrate for acute coronavirus disease 2019
por: Chirinos, Julio A., et al.
Publicado: (2022) -
Calprotectin and Imbalances between Acute-Phase Mediators Are Associated with Critical Illness in COVID-19
por: Kassianidis, Georgios, et al.
Publicado: (2022) -
COVID-19: Second Wave or Multiple Peaks, Natural Herd Immunity or Vaccine – We Should be Prepared
por: Moghnieh, Rima, et al.
Publicado: (2020) -
Parity and diabetes risk among hispanic women from Colombia: cross-sectional evidence
por: Cure, Pablo, et al.
Publicado: (2015) -
Alpha-lipoic acid may protect patients with diabetes against COVID-19 infection
por: Cure, Erkan, et al.
Publicado: (2020)